Search results
Showing 166 to 180 of 1242 results for public health guidance
In development Reference number: GID-TA11330 Expected publication date: 14 October 2026
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]
In development Reference number: GID-TA11230 Expected publication date: 19 August 2026
In development Reference number: GID-TA11186 Expected publication date: TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
In development Reference number: GID-TA11509 Expected publication date: 24 February 2027
We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: 03 September 2026
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
In development Reference number: GID-TA11768 Expected publication date: 28 October 2026
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Awaiting development Reference number: GID-TA10879 Expected publication date: 11 November 2026
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection